HEM Pharma Inc
376270
Company Profile
Business description
HEM Pharma Inc is a microbiome-specialized healthcare company that operates a customized healthcare business and an LBP (Live Biotherapeutic Products) discovery platform business utilizing PMAS (Personalized Pharmaceutical Metal-Analytical Screening), a gut microbiome simulation technology. Its technology includes PMAS, MBR, Multi-omics, Microbiome, and Metabolome.
Contact
558, Handong-ro, Heunghae-eup
F102ho, 102ho
Gyeongsangbuk-do
Buk-gu
Pohang-si
KORT: +82 18994258
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
110
Stocks News & Analysis
stocks
Has the most hated company on the ASX 200 bounced back?
Encouraging results indicate a potential turnaround story.
stocks
Amazon earnings: Good results, with AWS still a winner; fear on profitability guidance is overblown
We think Amazon stock looks attractive.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,922.00 | 77.00 | -0.86% |
| CAC 40 | 7,630.10 | 83.94 | 1.11% |
| DAX 40 | 23,757.28 | 331.31 | 1.41% |
| Dow JONES (US) | 44,070.51 | 60.47 | -0.14% |
| FTSE 100 | 9,127.08 | 5.73 | -0.06% |
| HKSE | 24,733.45 | 39.88 | -0.16% |
| NASDAQ | 20,971.09 | 320.95 | 1.55% |
| Nikkei 225 | 40,290.70 | 779.12 | -1.90% |
| NZX 50 Index | 12,684.04 | 139.70 | -1.09% |
| S&P 500 | 6,311.97 | 73.96 | 1.19% |
| S&P/ASX 200 | 8,663.70 | 79.10 | -0.90% |
| SSE Composite Index | 3,583.31 | 23.36 | 0.66% |